Browsing Haematology (Scholarly Publications) by Author "Morris, Curly"
Now showing items 1-2 of 2
-
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Browne, Paul; Sahebi, Firoozeh; Iacobelli, Simona; Sbianchi, Giulia; Koster, Linda; Blaise, Didier; Reményi, Péter; Russell, Nigel H.; Ljungman, Per; Kobbe, Guido; Apperley, Jane; Trneny, Marek; Krejci, Marta; Wiktor-Jedrzejczak, Wieslaw; Sanchez, James F.; Schaap, Nicolaas; Isaakson, Cecilia; Lenhoff, Stig; Scheid, Christof; Wilson, Keith M.O.; Yakoub-Agha, Ibrahim; González Muñiz, Soledad; Schönland, Stefan; Morris, Curly; Garderet, Laurent; Kröger, Nicolaus (2018)The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective ... -
Melphalan 140 mg/m2or 200 mg/m2for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party
Browne, Paul; Auner, Holger W.; Iacobelli, Simona; Sbianchi, Giulia; Knol-Bout, Cora; Blaise, Didier; Russell, Nigel H.; Apperley, Jane F.; Pohlreich, David; Kobbe, Guido; Isaksson, Cecilia; Lenhoff, Stig; Scheid, Christof; Touzeau, Cyrille; Jantunen, Esa; Anagnostopoulos, Achilles; Yakoub-Agha, Ibrahim; Tanase, Alina; Schaap, Nicolaas; Wiktor-Jedrzejczak, Wieslaw; Krejci, Marta; Schönland, Stefan O.; Morris, Curly; Garderet, Laurent; Kröger, Nicolaus (2018)Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived ...